Page 24 - 《中国药科大学学报》2025年第5期

556 学报 Journal of China Pharmaceutical University 2025, 56(5): 548 − 556 第 56 卷

lethality[J]. Front Oncol, 2023, 13: 1264785. [27] Abbisko therapeutics co Ltd. Nitrogen-containing fused three
[15] Mavrakis KJ, Robert McDonald E 3rd, Schlabach MR, et al. ring PRMT5 inhibitor, and preparation method therefor and
Disordered methionine metabolism in MTAP/CDKN2A-delet- pharmaceutical use thereof: WO2024027370A1[P]. 2024-02-
ed cancers leads to dependence on PRMT5[J]. Science, 2016, 08[2025-01-28].
351(6278): 1208-1213. [28] Tango Therapeutics Inc. Piperidin-1-yl-N-pyridin-3-yl-2-oxoac-
[16] Marjon K, Cameron MJ, Quang P, et al. MTAP deletions in etamide derivatives useful for the treatment of MTAP-deficient
cancer create vulnerability to targeting of the and/or MTA-accumulating cancers: WO2022026892A1[P].
MAT2A/PRMT5/RIOK1 axis[J]. Cell Rep, 2016, 15(3): 574- 2022-02-03[2025-01-28].
587. [29] Briggs KJ, Tsai A, Zhang MJ, et al. Abstract 4970: TNG462 is
[17] Hu M, Chen X. A review of the known MTA-cooperative a potential best-in-class MTA-cooperative PRMT5 inhibitor for
PRMT5 inhibitors[J]. RSC Adv, 2024, 14(53): 39653-39691. the treatment of MTAP-deleted solid tumors[J]. Cancer Res,
[18] Smith CR, Kulyk S, Ahmad MUD, et al. Fragment optimiza- 2023, 83(Suppl 7): 4970.
tion and elaboration strategies–the discovery of two lead series [30] Cottrell KM, Briggs KJ, Whittington DA, et al. Discovery of
of PRMT5/MTA inhibitors from five fragment hits[J]. RSC Med TNG908: a selective, brain penetrant, MTA-cooperative
Chem, 2022, 13(12): 1549-1564. PRMT5 inhibitor that is synthetically lethal with MTAP-deleted
[19] Smith CR, Aranda R, Bobinski TP, et al. Fragment-based dis- cancers[J]. J Med Chem, 2024, 67(8): 6064-6080.
covery of MRTX1719, a synthetic lethal inhibitor of the [31] Briggs KJ, Cottrell KM, Tonini MR, et al. TNG908 is a brain-
PRMT5•MTA complex for the treatment of MTAP-deleted can- penetrant, MTA-cooperative PRMT5 inhibitor developed for the
cers[J]. J Med Chem, 2022, 65(3): 1749-1766. treatment of MTAP-deleted cancers[J]. Transl Oncol, 2025, 52:
[20] Smith CR, Aranda R, Christensen JG, et al. Design and evalua- 102264.
tion of achiral, non-atropisomeric 4-(aminomethyl)phthalazin- [32] Zhang MJ, Tsai A, Cottrell K, et al. DDDR-33. TNG908, a
1(2H)-one derivatives as novel PRMT5/MTA inhibitors[J]. brain-penetrant mta-cooperative PRMT5 inhibitor, is effica-
Bioorg Med Chem, 2022, 71: 116947. cious in preclinical MTAP-deleted models including glioblas-
[21] Belmontes B, Slemmons KK, Su C, et al. AMG 193, a clinical toma[J]. Neuro-Oncology, 2023, 25(Suppl 5): v113.
stage MTA-cooperative PRMT5 inhibitor, drives antitumor ac- [33] Cottrell KM, Briggs KJ, Tsai A, et al. Discovery of TNG462: a
tivity preclinically and in patients with MTAP-deleted highly potent and selective MTA-cooperative PRMT5 inhibitor
cancers[J]. Cancer Discov, 2025, 15(1): 139-161. to target cancers with MTAP deletion[J]. J Med Chem, 2025,
[22] Sarvary I, Vestergaard M, Moretti L, et al. From DNA-encoded 68(5): 5097-5119.
library screening to AM-9747: an MTA-cooperative PRMT5 in- [34] AstraZeneca AB. MTA-cooperative PRMT5 inhibitors for use
hibitor with potent oral in vivo efficacy[J]. J Med Chem, 2025, in the treatment of cancer: WO2024038004A1[P]. 2024-02-
68(6): 6534-6557. 22[2025-01-28].
[23] Amgen Inc. AMG 193 alone or in combination with other thera- [35] AstraZeneca AB. Spirocyclic compounds: WO2023036974A1
pies in subjects with advanced thoracic tumors with homozy- [P]. 2023-03-16[2025-01-28].
gous MTAP-deletion (master protocol)[EB/OL]. (2025-04- [36] Smith JM, Barlaam B, Beattie D, et al. Discovery and in vivo
04)[2025-04-07]. https://clinicaltrials.gov/study/NCT06333951. efficacy of AZ-PRMT5i-1, a novel PRMT5 inhibitor with high
[24] Amgen Inc. A study evaluating AMG 193 in combination MTA cooperativity[J]. J Med Chem, 2024, 67(16): 13604-
with other therapies in participants with advanced gastrointesti- 13638.
nal, biliary tract, or pancreatic cancers with homozygous [37] Spira AI, Lau J, Hattersley MM, et al. PRIMROSE: a modular
methylthioadenosine phosphorylase (MTAP)-deletion[EB/OL]. phase 1/2a study of AZD3470, an MTA-cooperative PRMT5 in-
(2025-04-04)[2025-04-07]. https://clinicaltrials.gov/study/ hibitor, in patients with MTAP deficient advanced solid
NCT06360354. tumors[J]. J Clin Oncol, 2024, 42(Suppl 16): TPS3179.
[25] Amgen Inc. A phase 1/2 study of AMG 193 in combination [38] Smith J, Urosevic J, Moore S, et al. First disclosure of
with IDE397 in participants with advanced methylthioa- AZD3470, a highly potent MTA-cooperative PRMT5 inhibitor
denosine phosphorylase (MTAP)-null solid tumors[EB/OL]. in PRIMROSE and PRIMAVERA clinical studies[J]. Eur J
(2025-02-27)[2025-04-07]. https://clinicaltrials.gov/study/ Cancer, 2024, 211: 114668.
NCT05975073. [39] Gjuka D, Adib E, Garrison K, et al. Enzyme-mediated deple-
[26] Shanghai apeiron therapeutics company Ltd. Novel PRMT5 in- tion of methylthioadenosine restores T cell function in MTAP-
hibitor and use Thereof: WO2024032572A1[P]. 2024-02- deficient tumors and reverses immunotherapy resistance[J].
15[2025-01-28]. Cancer Cell, 2023, 41(10): 1774-1787. e9.